Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.30 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469282 | 0.88 | NQO2 (0.45) | BCHENQO2PDE3BPDE3AKDM4E | |
| SCHEMBL17469279 | 0.86 | ENPP3 (0.38) | BCHEDYRK1ANQO2CFTRHDAC6 | |
| SCHEMBL17469274 | 0.86 | CYP3A4 (0.38) | BCHEDYRK1ANQO2CFTRHDAC6 | |
| SCHEMBL17469285 | 0.86 | CFTR (0.41) | BCHEDYRK1ANQO2CFTRHDAC6 | |
| SCHEMBL17469275 | 0.85 | BCHE (0.36) | BCHEDYRK1ANQO2HDAC6PDE3B | |
| SCHEMBL19317479 | 0.83 | — | — | |
| SCHEMBL19322129 | 0.82 | GAA (0.40) | BCHECFTRKDM4EMEN1MAPT | |
| SCHEMBL17469286 | 0.81 | BCHE (0.36) | BCHEDYRK1ANQO2PDE3BPDE3A | |
| SCHEMBL17469276 | 0.80 | MTNR1A (0.43) | BCHENQO2HDAC6KDM4EMTNR1A | |
| SCHEMBL19317480 | 0.78 | PDE3B (0.36) | NQO2PDE3BPDE3AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147795-B2 | Neuroprotective compounds and methods of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190350902-A1 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-11-21 | — | — | US | disclosed |
| US-10358438-B2 | [3+2] annulation to produce 5-membered heterocyclic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-07-23 | — | — | US | disclosed |
| US-20170253580-A1 | ORGANIC REACTIONS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2016014426-A1 | ORGANIC REACTIONS | THE ARIZONA BOARD OF REGENTS (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147795-B2 | Neuroprotective compounds and methods of use | RTN3, CHRNB3, ARRB1 | BCHE 1054/4885DYRK1A 1642/4885NQO2 1359/4885 |
| US-20170253580-A1 | ORGANIC REACTIONS | MYC, CYP2E1, CYP3A4 | BCHE 1609/4885DYRK1A 3353/4885NQO2 349/4885 |
| US-20190350902-A1 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE | RTN3, CHRNB3, ARRB1 | BCHE 1054/4885DYRK1A 1642/4885NQO2 1359/4885 |
| US-10358438-B2 | [3+2] annulation to produce 5-membered heterocyclic compounds | ACR, MYC, TOP1 | BCHE 2514/4885DYRK1A 4019/4885NQO2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.